Telix Pharma’s prostate cancer PET1 imaging agent, Illuccix receives European marketing approval: Melbourne, Australia Saturday, January 18, 2025, 10:00 Hrs [IST] Telix Pharmace ...

Most nuclear medicine technologists are employed in hospital settings, where they contribute to the diagnosis and treatment.

Telix Pharmaceuticals Limited today announces that it has received a positive decision on the Marketing Authorization ...

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive ...

Patient was not fit for Docetaxel therapy and he was put on monthly Denosumab injection 120 mg/1 syringe, and Abiraterone ...

Chief minister Sukhvinder Singh Sukhu says HIMCARE scheme is operational in all government hospitals of the state. “The BJP ...

This is just a sampling of medical advancements in 2024 chosen for their common presence in the American population. It is ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

Pills that prevent Alzheimer’s disease or blunt its effects are on the horizon, as the fight against dementia enters a “new era”, experts have said. Scientific advances were on the cusp of ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the closing of its previously announced ...

Illuccix is approved in Europe for PSMA-positive lesion detection in prostate cancer, following prior approvals in the US, Australia, and Canada. The phase 3 VISION trial showed 177Lu-PSMA-617 plus ...

VIENNA, Va., December 30, 2024--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of a ...